When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.
Emmaus Life Sciences
- The Trade: Emmaus Life Sciences, Inc. (OTC:EMMA) Chairman and CEO Yutaka Niihara acquired a total of 7700 shares at an average price of $1.48. To acquire these shares, it cost $11,426.00.
- What’s Happening: The company’s shares have jumped over 22% since the start of the year.
- What Emmaus Life Sciences Does: Emmaus Life Sciences Inc is a biopharmaceutical company engaged in the discovery, development, and commercialization of new treatments and therapies primarily for rare and orphan diseases.
PEDEVCO
- The Trade: PEDEVCO Corp. (NYSE:PED) CEO Simon Kukes acquired a total of 58271 shares at an average price of $1.12. The insider spent $65,088.71 to buy those shares.
- What’s Happening: PEDEVCO recently reported spudding of its first of 2 new horizontal wells in Permian Basin Asset.
- What PEDEVCO Does: PEDEVCO is an energy company. It is engaged in the acquisition, exploration, development, and production of oil and natural gas shale plays in the Denver-Julesberg Basin (D-J Basin) in Colorado.
TMC the metals company
- The Trade: TMC the metals company Inc. (NASDAQ:TMC) Director Andrei Karkar acquired a total of 748957 shares at an average price of $2.00. To acquire these shares, it cost $1,497,914.00.
- What’s Happening: The company’s stock dropped around 44% over the previous month.
- What TMC the metals company Does: TMC The Metals Co Inc is an explorer of lower-impact battery metals from seafloor polymetallic nodules. It supplies metals for the clean energy transition with the least possible negative environmental and social impact and accelerates the transition to a circular metal economy.
ProtoKinetix
- The Trade: ProtoKinetix, Incorporated (OTC:PKTX) President and CEO Clarence E. Smith acquired a total of 833333 shares at an average price of $0.06. The insider spent $49,999.98 to buy those shares.
- What’s Happening: ProtoKinetix, last month, reported selection of AAGP® candidate formulations for the treatment of dry eye disease.
- What ProtoKinetix Does: ProtoKinetix Inc is a research and development stage biotechnology company focused on scientific medical research of AFGPs (Anti-Freeze Glycoproteins).
